SCHEMBL4078682

SCHEMBL4078682

CC(C)(CO)Nc1nc(-c2cccc(Br)c2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
CSNK2A2 P19784 1/20 0.52
CSNK2B P67870 1/20 0.52
CSNK2A1 P68400 1/20 0.52
CSNK2A3 Q8NEV1 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 2/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
HK1 P19367 1/20 0.51
RAB9A P51151 1/20 0.51
HKDC1 Q2TB90 1/20 0.51
MAOA P21397 2/20 0.47
KDM1A O60341 1/20 0.47
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
GUSB P08236 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077729 0.84 MAPT (0.59) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL3166410 0.82 CYP1A1 (0.51) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL22299979 0.78 MAPT (0.62) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL4394378 0.78 MAPT (0.44) MEN1KMT2ACSNK2A1MAPTALDH1A1
SCHEMBL4076431 0.78 MEN1 (0.52) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL3977673 0.76 ABL1 (0.62) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL4075125 0.76 MEN1 (0.50) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL30294199 0.76 MAPT (0.67) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL10926224 0.75 MEN1 (0.71) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL22290428 0.75 MEN1 (0.70) MEN1KMT2ACSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR MEN1 699/4885KMT2A 667/4885CSNK2A2 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.